EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Efficacy of Erenumab in Patients With Treatment-Resistant Chronic Migraine and Medication Overuse Headache

Mohamed F Binfalah iD, Anwar A Alrayyes, Hussein H Alhafnawi, Moiz O Bakhiet

Neurosciences · 27.03.2026 · 31 (1) · 47-54

DOI: 10.17712/1658-3183.1006 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neurosciences, online erschienen am 27.03.2026. Verfasst von Mohamed F Binfalah und 3 weiteren Autor:innen. Beteiligte Einrichtung: MD, Consultant Neurologist, University Medical Center, Arabian Gulf University, Manama, Kingdom of Bahrain. Hauptthemen laut MEDLINE: Migraine Disorders, Headache Disorders, Secondary, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of erenumab, a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor, in patients with treatment-resistant chronic migraine and medication overuse headache.

Methods

A single-center, retrospective observational study conducted at University Medical Center on 73 patients with both medication-overuse headache and treatment-resistant chronic migraine who failed at least three oral preventive medications and/or botulinum toxin injections. Clinical data were extracted from the medical records and patient interviews. The patients received monthly erenumab injections 70 mg. Key outcomes included monthly migraine days, headache severity (visual analog scale [VAS]), headache impact test (HIT-6), acute medication use, and global impression of change (PGIC) over a 3-month follow-up period.

Results

Significant reductions were observed in monthly migraine days (mean: 12.3 days, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersHeadache Disorders, SecondaryAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsHumansFemaleMaleAdultRetrospective StudiesMiddle AgedTreatment OutcomeChronic Disease

Stichwörter der Autor:innen

CGRPErenumabGlobal impression of changeHeadache burdenMedication overuse headacheSide effects

Substanzen

erenumabAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • MD, Consultant Neurologist, University Medical Center, Arabian Gulf University, Manama, Kingdom of Bahrain.
  • MD, Attending Emergency Medicine and Pain Management, InMedic Pain Management Centres, Windsor, ON N8N 3T6, Canada.
  • BSc, Clinical Research Coordinator, Arabian Gulf University, Manama, Kingdom of Bahrain.
  • MD, PhD, Consultant Neurologist and Professor of Molecular Medicine, Aljawhara Center, Department of Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain.

ORCID-Profile: Mohamed F Binfalah

Zitieren

APA

Binfalah, M. F., Alrayyes, A. A., Alhafnawi, H. H., & Bakhiet, M. O. (2026). Efficacy of Erenumab in Patients With Treatment-Resistant Chronic Migraine and Medication Overuse Headache. Neurosciences, 31(1), 47-54. https://doi.org/10.17712/1658-3183.1006

Vancouver

Binfalah MF, Alrayyes AA, Alhafnawi HH, Bakhiet MO. Efficacy of Erenumab in Patients With Treatment-Resistant Chronic Migraine and Medication Overuse Headache. Neurosciences. 2026;31(1):47-54. doi:10.17712/1658-3183.1006

BibTeX
@article{Binfalah2026,
  author = {Binfalah, Mohamed F and Alrayyes, Anwar A and Alhafnawi, Hussein H and Bakhiet, Moiz O},
  title = {Efficacy of Erenumab in Patients With Treatment-Resistant Chronic Migraine and Medication Overuse Headache},
  journal = {Neurosciences},
  year = {2026},
  volume = {31},
  number = {1},
  pages = {47--54},
  doi = {10.17712/1658-3183.1006}
}
Kostenlos starten →